Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.72 |
| ▸ | PAM | P19021 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27681753 | 1.00 | DGKA (0.72) | DGKAPAMTSHRMAPTCYP1A2 | |
| Ammonia Solution, Strong SCHEMBL11147784 | 1.00 | DGKA (0.72) | DGKAPAMTSHRMAPTCYP1A2 | |
| Ammonia Solution, Strong SCHEMBL27753086 | 1.00 | DGKA (0.72) | DGKAPAMTSHRMAPTCYP1A2 | |
| Ammonia Solution, Strong SCHEMBL27880730 | 1.00 | DGKA (0.72) | DGKAPAMTSHRMAPTCYP1A2 | |
| Ammonia Solution, Strong SCHEMBL21219078 | 1.00 | DGKA (0.72) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL116995 | 0.98 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| Hexane SCHEMBL2349171 | 0.98 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL454 | 0.98 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| Hexane SCHEMBL3138126 | 0.98 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL8375548 | 0.98 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
| US-20090318695-A1 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-24 | — | — | US | disclosed |
| WO-2009155403-A2 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-23 | — | — | WO | disclosed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | disclosed |
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | GIBSON STEPHEN PAUL (GB) | 2003-01-02 | — | — | US | disclosed |
| US-20020099216-A1 | Compounds useful in therapy | PFIZER INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| CN-1054376-C | Substituted 1H-imidazoles | UCB SA (BE) | 2000-07-12 | — | — | CN | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| US-5658938-A | HYPOTENSIVE AGENT, ANTIISCHMIC AGENTS | U C B S.A. (BE) | 1997-08-19 | — | — | US | disclosed |
| CN-1133837-A | Substituted 1H-imidazoles | UCB SA (BE) | 1996-10-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | DGKA 1746/4885PAM 3127/4885TSHR 3143/4885 |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | DGKA 3000/4885PAM 453/4885TSHR 338/4885 |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | DGKA 3457/4885PAM 1026/4885TSHR 2684/4885 |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | DGKA 3457/4885PAM 1026/4885TSHR 2684/4885 |
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | HRH2, HRH4, HRH1 | DGKA 2542/4885PAM 1391/4885TSHR 1129/4885 |
| US-20090318695-A1 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | COMT, CYP3A7, CHRNA7 | DGKA 3174/4885PAM 741/4885TSHR 3799/4885 |
| US-20020099216-A1 | Compounds useful in therapy | OPRD1, OPRL1, OPRM1 | DGKA 2949/4885PAM 1751/4885TSHR 433/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | DGKA 3000/4885PAM 453/4885TSHR 338/4885 |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | DGKA 1746/4885PAM 3127/4885TSHR 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.